Skip to content

Author

Hiroshige Yoshioka

We have 3 of 36 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

A phase II study of DFP-14323, a non-specific immunomodulator, in combination with low-dose afatinib as first-line therapy for common EGFR mutation-positive NSCLC

Background Aminopeptidase N (CD13) has been reported to be a prognostic factor in non-small cell lung cancer (NSCLC). DFP-14323 (INN: ubenimex) is a CD13 inhibitor and a low-toxicity, non-specific immunomodulator approved in Japan for the maintenance treatment of adult acute non-lymphocytic leukemia. Objectives This st...

Hiroshige Yoshioka, Masahide Mori, N. Katakami et al. · 0 citations
Open access Aug 2026

Population Decline May Affect the Incidence of Pulmonary Tuberculosis in Japan

It is revealed that younger foreign workers from countries with a high incidence of tuberculosis are more likely to develop pulmonary tuberculosis in Japan and more effective pre-entry tuberculosis screening should be introduced for young migrant workers from countries with a high incidence of tuberculosis.

Akihiro Miyauchi, Mizuki Inaba, Takatoshi Tetsuka et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.